Communiqués Adhera Therapeutics, Inc.

Actions

ATRX

US00687E4061

Marché Fermé - OTC Markets Autres places de cotation 21:17:04 11/06/2024			Varia. 5j.	Varia. 1 janv.
0,0043 ^USD	+2,38%		+4,88%	-85,67%

18/01	Adhera Therapeutics, Inc. reçoit une notification écrite de Melior Pharmaceuticals II, LLC de son choix de résilier l'accord de licence	CI
16/01	Adhera Therapeutics, Inc. annonce la démission de Zahed Subhan en tant que directeur général	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

BigTime Penny Stocks: OTCQB Venture Market Watchlist (WOEN, ATRX, EDXC, CBDS, OMTK)	17/10/23	AQ
Thinking about buying stock in Vistagen Therapeutics, Origin Materials, MedAvail Holdings, United States Lime & Minerals, or Adhera Therapeutics?	10/08/23	PR
Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist	19/09/22	AQ
ADHERA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure (form 8-K)	09/09/22	AQ
ADHERA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	25/08/22	AQ
ADHERA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	15/08/22	AQ
ADHERA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	04/08/22	AQ
Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin	19/07/22	AQ
Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ	19/05/22	AQ
ADHERA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	16/05/22	AQ
ADHERA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	15/04/22	AQ
Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board	21/03/22	AQ
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace	20/01/22	AQ
Adhera Therapeutics : OTCQB Certification	17/12/21	PU
Adhera Therapeutics : Report of Independent Registered Public Accounting Firm	15/12/21	PU
ADHERA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22/11/21	AQ
ADHERA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	12/11/21	AQ
ADHERA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (form 8-K)	27/10/21	AQ
Adhera Therapeutics : Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications	20/10/21	AQ
ADHERA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	13/10/21	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Adhera Therapeutics, Inc.

Actions

ATRX

US00687E4061

Communiqués

Filtres